TGTX vs. MOR, RNA, FOLD, ARWR, MRVI, CORT, MRUS, BHC, MLTX, and XENE
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include MorphoSys (MOR), Avidity Biosciences (RNA), Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), Maravai LifeSciences (MRVI), Corcept Therapeutics (CORT), Merus (MRUS), Bausch Health Companies (BHC), MoonLake Immunotherapeutics (MLTX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
TG Therapeutics (NASDAQ:TGTX) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation.
In the previous week, MorphoSys had 9 more articles in the media than TG Therapeutics. MarketBeat recorded 10 mentions for MorphoSys and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.08 beat MorphoSys' score of 0.61 indicating that TG Therapeutics is being referred to more favorably in the media.
TG Therapeutics currently has a consensus price target of $29.83, indicating a potential upside of 71.26%. MorphoSys has a consensus price target of $11.78, indicating a potential downside of 39.09%. Given TG Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe TG Therapeutics is more favorable than MorphoSys.
TG Therapeutics has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics has a net margin of 14.24% compared to MorphoSys' net margin of -226.79%. TG Therapeutics' return on equity of 31.34% beat MorphoSys' return on equity.
TG Therapeutics has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
TG Therapeutics received 626 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 9.2% of TG Therapeutics shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
TG Therapeutics beats MorphoSys on 15 of the 18 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
